TY - JOUR
T1 - Tumor Vasculatures
T2 - A New Target for Cancer Immunotherapy
AU - Liu, Zhigang
AU - Wang, Y.
AU - Huang, Y.
AU - Kim, Betty Y.S.
AU - Shan, Hong
AU - Wu, D.
AU - Jiang, Wen
N1 - Funding Information:
This work is supported by the National Natural Science Foundation of China ( 81572500 to Z.L.; 81673004 to Y.H.; 81430041 to H.S.), National Program on Key Basic Research Project of China (No. 2018YFC0910600 to H.S.), the Cancer Prevention and Research Institute of Texas ( RR180017 to W.J.), the National Cancer Institute ( K08CA241070 to W.J.) and the National Institute of Neurological Disorders and Stroke ( R01 NS104315 to B.Y.S.K.). We also would like to thank Jonathan Feinberg of the Department of Radiation Oncology at The University of Texas Southwestern Medical Center for assistance with editing the manuscript.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/9
Y1 - 2019/9
N2 - Immune cells rely on a functional vascular network to enter tissues. In solid tumors, blood vessels are abnormal and dysfunctional and, thus, immune effector cell infiltration is impaired. Although normalizing the tumor vasculature has been shown to improve the efficacy of cancer immunotherapies, recent studies suggest that enhanced immune stimulation also, in turn, improves tumor vascular normalization. Thus, this new paradigm of immune system–tumor vasculature mutual reprogramming opens the possibility of identifying new cancer treatment strategies that combine vascular targeting and immunotherapies. Here, we highlight current evidence supporting immune system–tumor vasculature crosstalk and outline how this relationship can provide new rationales for developing more effective combination immunotherapy strategies for treating human cancers.
AB - Immune cells rely on a functional vascular network to enter tissues. In solid tumors, blood vessels are abnormal and dysfunctional and, thus, immune effector cell infiltration is impaired. Although normalizing the tumor vasculature has been shown to improve the efficacy of cancer immunotherapies, recent studies suggest that enhanced immune stimulation also, in turn, improves tumor vascular normalization. Thus, this new paradigm of immune system–tumor vasculature mutual reprogramming opens the possibility of identifying new cancer treatment strategies that combine vascular targeting and immunotherapies. Here, we highlight current evidence supporting immune system–tumor vasculature crosstalk and outline how this relationship can provide new rationales for developing more effective combination immunotherapy strategies for treating human cancers.
KW - cancer immunotherapy
KW - immune checkpoint blockade
KW - tumor microenvironment
KW - tumor vasculature
KW - vascular normalization
UR - http://www.scopus.com/inward/record.url?scp=85069602962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069602962&partnerID=8YFLogxK
U2 - 10.1016/j.tips.2019.07.001
DO - 10.1016/j.tips.2019.07.001
M3 - Review article
C2 - 31331639
AN - SCOPUS:85069602962
SN - 0165-6147
VL - 40
SP - 613
EP - 623
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
IS - 9
ER -